Merck licenses Chinese cancer drug

Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.
Merck Snags Chinese Cancer Drug in Deal Worth Up to $3.3 Billion
Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront, plus as much as $2.7 billion in milestone payments.
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from LaNova Medicines, a Shanghai-based firm, for $588 million upfront and as much as $2.7 billion in potential milestone payments.
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday. The deal allows Merck to take over development of LaNova's LM-299,
Merck to buy rights to Chinese cancer drug for up to $3.3B
Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected to obtain licensing rights to a cancer candidate known as LM-299 from the Chinese biotech in a deal worth up to $3.
Pharmalittle: We’re reading about a Merck deal, GSK cancer drug data, and more
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company
Bristol Myers Faces Renewed, $6.7 Billion Lawsuit Over Delayed Cancer Drug
The lawsuit accused Bristol Myers of depriving holders of "contingent value rights" (CVR) an extra $9 per share in cash by ...
News Medical on MSN2h
New drug strategy reverses resistance to immunotherapy in pancreatic cancer
A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...
Sino Biopharmaceutical Gains FDA Approval for New Cancer Drug
Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical has received approval from the U.S. FDA to commence Phase I ...
The University of Chicago Chronicle10h
Argonne, UChicago partner to accelerate discovery of new cancer therapies using AI
The UChicago Medicine team will be led by Odunsi as co-principal investigator and includes Christopher Weber, Savas Tay, and ...
Drugs like Ozempic may be better at treating alcoholism than leading meds, new study finds
Lähteenvuo notes that while more research is called for, drugs like Ozempic may offer hope to those burdened by addiction, ...
Crain's Chicago Business10h
UChicago to harness Argonne's AI, supercomputer tools for cancer drug discovery
With a federal grant in hand, researchers at the health system and national lab will try to hit fast forward on the long and ...
Genetic variation enhances cancer drug sensitivity in specific patient groups, study shows
By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against ...
New RAS Gene Discovery Unveils Hidden Pathway Driving Cancer Growth
These findings could pave the way for new treatment approaches for cancers driven by RAS mutations. Researchers at the ...
GSK’s Withdrawn Blood Cancer Drug Reduced Risk of Death in Trial
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
Medscape2d
‘Nonsensical’ Limits on Supportive Drugs Complicate Cancer Care
A young woman with breast cancer was experiencing ... Chino told Medscape Medical News. Those limits are “a slightly ...